Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Impel Pharmaceuticals Inc. (IMPL)

2.72   -0.01 (-0.37%) 11-25 13:00
Open: 2.7 Pre. Close: 2.73
High: 2.84 Low: 2.68
Volume: 13,845 Market Cap: 65(M)

Technical analysis

as of: 2022-11-25 1:57:59 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.29     One year: 5.08
Support: Support1: 2.57    Support2: 2.14
Resistance: Resistance1: 3.67    Resistance2: 4.34
Pivot: 3.23
Moving Average: MA(5): 2.7     MA(20): 3.4
MA(100): 6.15     MA(250): 7.08
MACD: MACD(12,26): -0.6     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 7.4     %D(3): 6.3
RSI: RSI(14): 25.2
52-week: High: 10.75  Low: 2.57
Average Vol(K): 3-Month: 46 (K)  10-Days: 51 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IMPL ] has closed above bottom band by 25.4%. Bollinger Bands are 31.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.81 - 2.83 2.83 - 2.84
Low: 2.55 - 2.56 2.56 - 2.58
Close: 2.7 - 2.73 2.73 - 2.76

Company Description

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Headline News

Sat, 26 Nov 2022
In Gujarat, BJP promises 20 lakh jobs, Uniform Civil Code implementation - Hindustan Times

Tue, 15 Nov 2022
IMPL stock downgraded at Wedbush on sales outlook for migraine therapy (NASDAQ:IMPL) - Seeking Alpha

Mon, 14 Nov 2022
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 18 Oct 2022
Further weakness as Impel Pharmaceuticals (NASDAQ:IMPL) drops 15% this week, taking one-year losses to 56% - Simply Wall St

Thu, 15 Sep 2022
Convergence: EU official says no delay to CTIS implementation, despite industry concerns - Regulatory Focus

Tue, 16 Aug 2022
Loss-Making Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Expected To Breakeven In The Medium-Term - Simply Wall St

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -66 (M)
Shares Float 0 (M)
% Held by Insiders 2.374e+007 (%)
% Held by Institutions 1.047e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -23000
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -4.57
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 84.9
Return on Equity (ttm) -49.2
Qtrly Rev. Growth 8.22e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.6
Qtrly Earnings Growth -8.799e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.6
Price to Sales 688.66
Price to Cash Flow 0

Stock Dividends

Dividend 294530
Forward Dividend 422530
Dividend Yield 10828300%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.